Mitchell L. Shiffman

1990–2025 年に発表

別表記
MITCHELL L. SHIFFMAN
141
論文数
54,882
被引用数
104
h 指数
141
i10 指数

被引用数

Mitchell L. Shiffman の年別被引用数1986 年: 被引用 2 件1987 年: 被引用 1 件1991 年: 被引用 2 件1992 年: 被引用 2 件1993 年: 被引用 5 件1994 年: 被引用 2 件1995 年: 被引用 7 件1996 年: 被引用 14 件1997 年: 被引用 8 件1998 年: 被引用 31 件1999 年: 被引用 72 件2000 年: 被引用 158 件2001 年: 被引用 191 件2002 年: 被引用 360 件2003 年: 被引用 378 件2004 年: 被引用 454 件2005 年: 被引用 492 件2006 年: 被引用 520 件2007 年: 被引用 479 件2008 年: 被引用 466 件2009 年: 被引用 415 件2010 年: 被引用 512 件2011 年: 被引用 453 件2012 年: 被引用 448 件2013 年: 被引用 389 件2014 年: 被引用 393 件2015 年: 被引用 380 件2016 年: 被引用 336 件2017 年: 被引用 271 件2018 年: 被引用 246 件2019 年: 被引用 765 件2020 年: 被引用 886 件2021 年: 被引用 946 件2022 年: 被引用 745 件2023 年: 被引用 574 件2024 年: 被引用 804 件2025 年: 被引用 486 件2026 年: 被引用 21 件1988〜1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,891 件、この内訳の 28.4%中国: 引用元論文 934 件、この内訳の 6.8%イギリス: 引用元論文 829 件、この内訳の 6.1%イタリア: 引用元論文 814 件、この内訳の 5.9%ドイツ: 引用元論文 773 件、この内訳の 5.6%フランス: 引用元論文 712 件、この内訳の 5.2%スペイン: 引用元論文 499 件、この内訳の 3.6%カナダ: 引用元論文 497 件、この内訳の 3.6%日本: 引用元論文 472 件、この内訳の 3.5%オーストラリア: 引用元論文 354 件、この内訳の 2.6%オランダ: 引用元論文 271 件、この内訳の 2%スイス: 引用元論文 269 件、この内訳の 2%
0%28.4%その他 24.7%

分野

  • Medicine90.3%
  • Biochemistry, Genetics and Molecular Biology4.8%
  • Immunology and Microbiology1.9%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Neuroscience0.4%
  • Agricultural and Biological Sciences0.3%
  • その他1.5%

トピック

  • Liver Disease Diagnosis and Treatment17.7%
  • Hepatitis C virus research11.8%
  • Hepatitis B Virus Studies6.5%
  • Liver Disease and Transplantation6.4%
  • Liver Diseases and Immunity3.8%
  • Diet, Metabolism, and Disease3.1%
  • その他50.7%

共著者

全論文

検索で開く
  1. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark Pruzanski, Д. А. Шапиро - New England Journal of Medicine 2016 被引用: 1,108

  2. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John Bate, Mark Danta, Jacob George, Alexander Hodge, Nickolas Kontorinis, S.A. Roberts, Santosh Sanagapalli, Richard Skoien, Alexander Thompson, Amany Zekry, Rudolf Stauber, Michael Trauner, Christophe Moreno, Hendrik Reynaert, Len Verbeke, Mário Reis Álvares‐da‐Silva, Edison Roberto Parise, Cláudia P. Oliveira, Roberta Chaves Araújo, Ana de Lourdes Candolo Martinelli, Meredith A. Borman, Natasha Chandok, Magdy Elkhashab, Hughie F. Fraser, Kelly Kaita, Mang Ma, Paul Marotta, Alnoor Ramji, Edward Tam, Eric M. Yoshida, Mark G. Swain, Giada Sebastiani, Denis Petrunia, Armand Abergel, Rodolphe Anty, Marc Bourlière, Jérôme Boursier, Christophe Bureau, Laurent Castéra, François Habersetzer, Christophe Hézode, V. de Lédinghen, Vincent Leroy, V. Loustaud‐Ratti, Philippe Mathurin, Stanislas Pol, Fabien Zoulim, Holger Hinrichsen, Patrick Ingiliz, Frank Lammert, Michael Manns, Jörn M. Schattenberg, Ingolf Schiefke, Christian Trautwein, Stefan Zeuzem, Aric J. Hui, K Li, Vincent Wai‐Sun Wong, Subrat Kumar Acharya, Abhijit Chowdhury, Ajay Duseja, Dharmesh Kapoor, Shrikant Mukewar, Shiv Kumar Sarin, Samir Shah, S. Shalimar, Ajit Sood, BV Tantry, Ziv Ben‐Ari, Helena Katchman ほか 540 名 - Journal of Hepatology 2020 被引用: 466

  3. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jörn M. Schattenberg - New England Journal of Medicine 2023 被引用: 263

  4. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitchell L. Shiffman, Simone I. Strasser, Vincent Wai‐Sun Wong, Naim Alkhouri, for the ATLAS Investigators - Hepatology 2020 被引用: 278

  5. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nyingi Kemmer, Kris V. Kowdley, Michelle Lai, Eric Lawitz, Rohit Loomba, Mazen Noureddin, Angelo H. Paredes, Mary E. Rinella, Don C. Rockey, Miguel Rodriguez, Raymond A. Rubin, Michael Ryan, Arun J. Sanyal, Andrew Scanga, Thomas Sepe, Mitchell L. Shiffman, Mitchell L. Shiffman, Brent Tetri, Paul J. Thuluvath, Dawn M. Torres, John M. Vierling, Julia Wattacheril, Amanda Weiland, Donald L. Zogg - Gastroenterology 2019 被引用: 344

  6. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities

    著者: , , , , , , , , - Gastroenterology 2001 被引用: 2,075

  7. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Hepatology 2020 被引用: 321

  8. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

    著者: , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2018 被引用: 372

  9. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

    著者: , , , , , , , , , , , , , , , , , , - Hepatology 2019 被引用: 389

  10. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

    著者: , , , , , , , , , , , , , , , , , , , - Hepatology 2019 被引用: 259

  11. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pietro Invernizzi, Palak Trivedi, Lisa Forman, David E.J. Jones, Stephen Ryder, Mark G. Swain, Alexandra Steinberg, Pol Boudes, Yun‐Jung Choi, Charles A. McWherter, ENHANCE Study Group* - Hepatology 2023 被引用: 113

  12. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease

    著者: , , , , , , , , , , , , , , , , , , , - Hepatology 2018 被引用: 193

  13. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Hepatology 2019 被引用: 266

  14. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexandra Steinberg, Mónika Varga, Harinder Chera, Robert L. Martin, Charles A. McWherter, Gideon M. Hirschfield - ˜The œLancet. Gastroenterology & hepatology 2017 被引用: 186

  15. Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values

    著者: , , , , , , , , , - Hepatology 2003 被引用: 1,198

  16. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zeid Kayali, Nyingi Kemmer, Kevin Korenblat, Ming‐Zong Lai, Charles Landis, E.J. Lawitz, William M. Lee, Steven D. Lidofsky, Edward Mena, Mazen Noureddin, Angelo H. Paredes, Nikolaos Pyrsopoulos, K. Rajender Reddy, M. Rinella, Don C. Rockey, Manuel Rodríguez, Michele B. Ryan, Souvik Sarkar, Sanjaya K. Satapathy, Andrew Scanga, Mitchell L. Shiffman, Mohammad Shadab Siddiqui, Douglas A. Simonetto, Wing‐Kin Syn, Paul J. Thuluvath, Ramesh Vemulapalli, John M. Vierling, Ziad Younes, Agustı́n Albillos, Juan Arenas Ruiz-Tapiador, Salvador Augustín, José Luís Calleja, J. Crespo Garcia, L. García Buey, Juan Carlos García‐Pagán, Càndid Villanueva, C. Bureau, N. Carbonell, Valériane Leroy, Pierre‐Emmanuel Rautou, HS Heinzow, Ingolf Schiefke, Alexander Zipprich, Annalisa Berzigotti, Beat Muellhaupt - Journal of Hepatology 2019 被引用: 156

  17. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Hepatology 2022 被引用: 79

  18. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

    著者: , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2019 被引用: 176

  19. Diagnosis and Management of Primary Biliary Cholangitis

    著者: , , , , , , - The American Journal of Gastroenterology 2018 被引用: 209

  20. Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial

    著者: , , , , , , , , , , - Clinical Gastroenterology and Hepatology 2010 被引用: 466

  21. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2008 被引用: 1,179

  22. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C†

    著者: , , , , , , , , , , , - Hepatology 2006 被引用: 517

  23. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations

    著者: , , , , , , , - The American Journal of Gastroenterology 2020 被引用: 104

  24. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , George Therapondos, Aasim Sheikh, Danielle Brandman, Lance L. Stein, Victor Ankoma‐Sey, Kalyan Ram Bhamidimarri, Charles Landis, Brett E. Fortune, Hugo E. Vargas, Manal F. Abdelmalek, B. Freilich, Don C. Rockey, John M. Vierling, H. Tatum, Michael P. Curry, Mitchell L. Shiffman, Kiran Bambha, Reem Ghalib, Amy Stratton, Nadeem Anwar, Stephen H. Caldwell, Ayman Koteish, Mohammad Siddiqui, Sammy Saab, Nikunj Shah, Anita Kohli, Mary E. Rinella, Souvik Sarkar, Dawn M. Torres, Elizabeth C. Verna, Ravi Ravendhran, Justin Reynolds, Ray Thomason, Ray Kim, Fernando E. Membreno, Simona Jakab, Stevan A. Gonzalez, Andrew P. Keaveny, Jen‐Jung Pan, Satinder Gill, Jonathan Huang, James Strobel, Amanda Wieland, Giuseppe Morelli, Thomas Amankonah, Marina Roytman, W Schmidt, Gary A. Abrams, Bhaktasharan Patel - Journal of Hepatology 2020 被引用: 61